Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04075305 · ClinicalTrials.gov registry record
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
A clinical trial of Breast Cancer and Prostate Cancer, sponsored by UMC Utrecht.
- Recruiting
- Registry status
- 8,000
- Enrollment target
- 18
- Study locations
NCT04075305 is a study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by UMC Utrecht. The registered enrollment target is 8,000 participants, above the 2,797-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (186% higher). The trial reports 18 study locations across 6 states.
The verdict
NCT04075305, a study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by UMC Utrecht.
- RECRUITING
- Registry status
- 8,000 participants
- Enrollment target
- 18
- Study locations
Study Summary
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Conditions Studied
Interventions
- RADIATION Radiation therapy
Study Locations (18)
Other
- Austin Health - Olivia Newton-John Cancer Wellness and Research Centre - Melbourne
- Insitut Jules Bordet - Brussels
- University Health Network - Princess Margaret Cancer Center - Toronto
- Universitätsklinikum Tübingen - Tübingen
- Università degli Studi di Brescia - Brescia
- IRCCS Ospedale Sacro Cuore Don Calabria - Negrar
- Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital - Amsterdam
- Radiotherapiegroep - Deventer
- Radiotherapeutisch Instituut Friesland (RIF) - Leeuwarden
- Radboud UMC - Nijmegen
- University Medical Center Utrecht - Utrecht
- The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre - London
- The Christie National Health Service Foundation Trust - Manchester
Pennsylvania
- Allegheny Health Network - Pittsburgh
Texas
- Md Anderson Cancer Center - Houston
Wisconsin
- Medical College of Wisconsin - Milwaukee
Ontario
- Sunnybrook Health Sciences Centre/Odette Cancer Centre - Toronto
Funen
- Odense Universitetshospital - Odense
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2030-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04075305
The ClinicalTrials.gov registry entry for NCT04075305 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,797-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (186% higher). The listed sponsor is UMC Utrecht, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation therapy is the first listed.
NCT04075305 reports 18 study locations spanning 6 distinct geographic areas - top geographies include Other, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT04075305 about?
NCT04075305 is a clinical study titled "The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study". The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose...
What is the current status of trial NCT04075305?
This trial is currently recruiting. The enrollment target is 8,000 participants. The study started on 2019-02-01. Estimated completion is 2030-08-01.
What conditions does trial NCT04075305 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Brain Tumor, Gynecologic Cancer, Brain Cancer.
What interventions are being tested in trial NCT04075305?
The interventions under investigation include: Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04075305?
This trial is sponsored by UMC Utrecht, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04075305 being conducted?
This trial has 18 study locations across Pennsylvania, Texas, Wisconsin, Ontario, Funen. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.